Atrandi Biosciences

Atrandi Biosciences is transforming single-cell analysis with its patented Semi-Permeable Capsule (SPC) technology, enabling scalable, true single-cell multiomics. By simplifying complex workflows, Atrandi accelerates discoveries in cellular heterogeneity, clonal evolution, microbiome diversity, microbial ecology, and more. Headquartered in Vilnius, Lithuania, the company is empowering scientists worldwide to push the boundaries of biological science. Its name, meaning "you discover" in Lithuanian, embodies the company's mission to enable researchers to uncover the unknown. 

Website: https://atrandi.com/

Categories: Biotechnology, Life Science, Pharmaceutical

Founded: 2016 

Founder(s): Juozas Nainys, Linas Mažutis,  Karolis Leonavičius, Dalius Kučiauskas, Rapolas Žilionis

Location(s): Vilnius, Lithuania

Entry date: 2019

Entry-stage: Seed

Latest stage: Early

Latest round: Series A

Co-investors: Lux Capital, Vsquared Ventures, Metaplanet, GRIDS Capital, Business Angels

Exit: n/a

News:

2021: Biotech Startup Droplet Genomics Raises €1 Million From Practica Capital To Commercialize Droplet Microfluidics Technology

2023: Atrandi Biosciences Secures Funding and Advances Global Commercialization of Next-Gen Single Cell Analysis Technology

2025: Atrandi Biosciences Raises $25M Series A to Drive the Future of Single-Cell Multiomics with Semi-Permeable Capsule Technology

 

Back to the list